The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Oops, clumsy thumbs, It was supposed to say ....OS I am the most risk adverse person I know. I don't believe anything I'm told without first corroborating it with my own research and experience. It isn't about risk avoidance,it is about risk management, which you will not do successfully if you never see positives too. Not bragging, just saying, I started out with no less shares than you, albeit at a lower price, and still have no less shares than you but at zero net cost now, because I traded them gently as the prices went up to 15 and then back down to <>3. I now adopt an method whereby I see the shares not as a pot but as a collection of smaller pots depending on purchase price, I associate a selling price with each of these pots which I can vary as I see fit. None of this is advice, but it works for me. At least have a plan.
OS I am the most risk adverse person I know. I don't believe anything I'm told without first corroborating it with my own research and experience. It isn't about risk avoidance,it is about risk management, which you will not do successfully if you never see positives too. Not bragging, just saying, net cost now, because I traded them gently as the prices went up to 15 and then back down to <>3. I now adopt an method whereby I see the shares not as a pot but as a collection of smaller pots depending on purchase price, I associate a selling price with each of these pots which I can vary as I see fit. None of this is advice, but it works for me. At least have a plan.
Re the cost of the buildings. The Company moved to its new site at Seven Hills, where a new 10-year lease, with two five-year extension options, was secured. These premises offer substantially more floor space and electrical power at a similar cost to Lane Cove. Fitting out these new buildings was completed under budget. So no issues there.
OS you are only in negative equity because the last time the share price rose through the teens and back you didn't sell, not a bean, when you could have made a nice profit. You are in negative equity either because you are greedy or don't understand AIM investing or both. You cannot blame AK, you can only look at yourself. Please do not make the same mistake again of not having a plan.
OS use Google, stop being a numpty. For instance https://www.incentiveadvisory.com.au/r-and-d-tax-incentives?utm_source=search&utm_medium=sem&utm_campaign=R%26D&gclid=CjwKCAiAnvj9BRA4EiwAuUMDfyZ7m4Eo51jZT4LcSS_1ko70-sRvY5r0kwcQ_mN1f7GcC6G1iNDMxBoCICgQAvD_BwE
https://www.sharesmagazine.co.uk/shares/share/CPX/trades has it :-Nov 23, 2020 08:34:19 4.82 139,474 672,264.68 . Looks like it was delayed due to size, the value of a tad over 672k is a very confident investment! I've told them about their bug.
Slightly-Super Friday. What's afoot? We all know the list of all the good things in the pipeline, but which of them triggered this afternoon's interest? Should we look forward to a Massively Manic Monday? ramp ramp ramp.
Careful PrivateRyan , that is 12 posts this week already, quite verbose for someone who would not be wasting any more time on this board. People in glass houses indeed. Few too many lemonades maybe. Go chase your rainbows at least with a glass half full not a glass half empty or even better a mug. Take care, stay safe. And no I'm not your mum.
Any vaccine that can be transported and stored at room temperature and can be self administered in going to have a much bigger market than those that need to be stored at -80 and need to be injected. If I was developing vaccines I would be looking very closely at Nuvec, I would already be in discussions and planning how to go ahead with trials when the time comes. Nuvec wasn't here before, maybe not ready for COVID 19 this time around, but there are still >6 billion people to vaccinate, there will be opportunity after opportunity. These partners will be paying up front for licences to use Nuvec for their trials, we don't need to wait for final approval before the commercial benefits can roll in.
I never understood why the SP dropped (mind you i didn't last time either). From the RNS of the 5th Nuvec could play two important roles in COVID vaccine delivery, first in storage and transportation, second via oral application. It needed a working vaccine for these two possibilities have legs, one pops up so you'd think that would have helped the SP.
@Vander. The 5/11 RNS stated regarding Oral Application that "the Company has now demonstrated that Nuvec® protects plasmid DNA from both acid and nuclease digestion. This result gives the Company confidence that further investigation of this route of administration using Nuvec® is merited". So not all subcutaneous, or do you see that differently?